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properties of the diseased arterial wall in addition to regression or preven-
tion of atherosclerosis. Perhaps more uniform circumferential distribution of
residual strain (vs. compliance mismatch) conferred by lipid reduction pre-
vents high circumferential stress regions and subsequent plaque rupture.
Conclusion; This high incidence of Chlamydia detected only in coronary
arteries diseased by atherosclerosis suggests an etiologic role for Chlamydia
infection in the development of coronary atherosclerosis, which should be
further studied.
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Early coronary atherosclerosis (CA) is characterized by endothelial dysfunc-
tion which is manifested by coronary vasoconstriction in response to the
endothelial-dependent vasodilator acetylcholine. The endothelium may be
involved in the adaptive process of vascular remodeling (VR). While vascu-
lar remodeling has been demonstrated in advanced CA, it is not known if
this process occurs early in the course of CA. Thus, this study was designed
to test the hypothesis that VR characterized by proximal coronary artery en-
largement occurs in patients with angiographically normal or mild CA and
abnormal coronary endothelial function. To test this hypothesis, 20 patients
found to have normal coronary angiograms or mild CA were studied. Acetyl-
choline was infused in incremental doses into the left anterior descending
(LAD) with angiographic measurement of lumen diameter. Patients were di-
vided into two groups based on their coronary endothelial function. Group
1 demonstrated coronary vasoconstriction in response to acetylcholine and
Group 2 had a normal vasodilatory response. Intravascular ultrasound mea-
surements of the proximal LAD diameter and area were made following ni-
troglycerin. Vessel diameter and area were measured at the internal elastic
membrane and indexed to body surface area (BSA). Comparison between
the two groups is outlined below:
Data are mean ± SEM, *p < 0.02 vs. Group 2
Five patients in Group 1 and one in Group 2 had ultrasound evidence of
mild atherosclerosis. This study demonstrates in vivo that vascular remod-
eling characterized by enlargement of the proximal coronary arteries occurs
early in the course of coronary disease in the presence of endothelial dys-
function.
9:45
Vascular Remodeling and Endothelial Dysfunction in
Coronary Disease
Charles R. Cannan, Stuart T. Higano, David R. Holmes Jr., Amir Lerman Mayo
Clinic, Rochester. MN
The renin-angiotensin and adrenergic nervous systems exhibit multiple lev-
els of cross-regulation in heart failure. These systems are bidirectionally
activated in concert; i.e. activation of one system activates the other. We
compared the behavior of angiotensin II AT1 and AT2 receptors with {1, -and
,62-adrenergic receptors in a high-yield crude membrane fraction prepared
from nonfailing and failing human ventricular myocardium. Ang II receptors
were measured by 1251saralasin binding, with 8max determined by satura-
tion binding displaceable by 1 JLM cold saralasin. ATl and AT2 receptorfrac-
tions were determined by the amount of specific binding displaceable by 1
JLM losartan. ~1-adrenergic receptor density was determined by saturation
binding of 12 I ICYP, with the ,61 fraction determined by binding displace-
able by 0.2 JLM CGP 20712A. Results in end-stage human left ventricular
myocardium failing as a result of idiopathic dilated cardiomyopathy were
compared to nonfailing controls taken from age- and gender-matched organ
donors not used for transplant because of blood type or body size mismatch:
(Receptor density is in fmol!mg ± SEM)
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In coronary angioplasty, the arterial wall is subjected to very high intraluminal
pressures, resulting in both stretch and crush of vascular cells. In an attempt
to investigate the respective effects of pressure-induced stretch and crush
on the induction of c-fos, c-jun and c-myc, an in vitro experimental model
was developed. Segments of descending rabbit thoracic aorta with intact
endothelium were canulated and excised at their in vivo length and main-
tained at physiological pressure level. Vessels were then incubated in bath
containing DMEM and antibiotics. The arterial segments were connected to
a mercury manometer or a coronary inflation device in order to rise the inter-
nal diameter from 4 to 6 mm (submaximal distension) for 2 minutes under
various levels of intraluminal pressure: A) 90 mmHg, which mimics phys-
iological conditions; B} 200 mmHg, the vessel diameter being maintained
at 6 mm using a rigid external support; C) 2 bars, using the same exter-
nal support. The intaluminal pressure was then brought back to its initial
value and the vessels were examined for protooncogenes expression using
Northern and slot blot analyses, 30 and 90 minutes thereafter. In addition, in
vivo experiments were conducted to determine protooncogenes expression
in thoracic aorta, 30 and 90 minutes following endothelial denudation by a
Fogarty balloon. We found that c-fos, c-jun and c-myc were induced in the
arterial wall after in vivo balloon denUdation. In organ culture, brief and un-
opposed stretch of the arterial wall (condition A) was not sufficient to induce
the expression of protooncogenes. In contrast, although the artery was kept
at the same level of stretch, crush of vascular cells under high intaluminal
pressures (200 mmHg and 2 bars) greatly increased the expression of c-fos,
c-jun and c-myc. The mRNA levels of these protooncogenes were propor-
tional to the magnitude of intraluminal pressure. Levels of c-fos and c-jun
mRNAs peaked at 30 minutes, while those of c-myc peaked at 90 minutes.
Since the contractility of aortic rings obtained from vessels studied under
each experimental condition was not altered, the increased expression of
protooncogenes observed under 200 mmHg and 2 bars cannot be viewed
as a signal of cell death.
Conclusion: These data suggest that brief, pressure-induced crush of vas-
cular cells in the arterial wall, is a potent stimulus for the induction of imme-
diate early genes implicated in cellular proliferation and vascular remodeling.
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Effects of Stretch and Pressure-induced Crush of the
Arterial Wall on the Induction of Immediate Early
Protooncogenes
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Increased Incidence of Chlamydia Bacteria Detected
within Coronary Arteries of Patients with
Atherosclerotic Versus Transplant Induced Coronary
Artery Disease
Joseph B. Muhlestein, Elizabeth H. Hammond, John F. Carlquist, Ellen Radicke,
Matthew J. Thomson, Daniel J. Parker, Labros A. Karagounis, Jeffrey L. Anderson
University of Utah, WS Hospital, Salt Lake City, Utah
Previous work has suggested an association between Chlamydia pneumo-
niae infection and coronary atherosclerosis, based on the demonstration of
increased serologic titers and the detection of bacteria within atherosclerotic
tissue. We sought to strengthen a possible etiologic link by comparing the
incidence of Chlamydia infection in coronary atherosclerotic tissue to that
in coronary arteries of patients with non-atherosclerotic cardiovascular dis-
ease.
Coronary tissue specimens obtained from 90 consecutive patients (mean
age = 57 yrs) with symptomatic coronary artery disease undergoing di-
rectional coronary atherectomy were tested for the presence of Chlamydia
species by direct immunofluorescence using mouse monoclonal antibody.
Immunofluorescence was positive in 68 (76%), equivocal in 5 (6%) and neg-
ative in 19 (21 %) of specimens. Polymerase chain reaction confirmed the
specific Chlamydia strain TWAR in 2 cases. No clinical factors except the
presence of a primary non-testenotic lesion (odds ratio = 3.0, p = 0.057)
predicted the detection of Chlamydia.
As a control, coronary tissue specimens from 11 patients with previous
cardiac transplantation and subsequent transplant-induced coronary artery
disease were also tested. Direct immunofluorescence performed on these
diseased coronary artery segments was negative for Chlamydia in every case
(p = 0.0001 compared with atherosclerotic specimens).
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Intact cNOS-NO-cGMP Pathway in the Failing Human
Heart
We previously have shown that the angiotensin II receptor. type 1a (ATlaR)
message transiently decreases during ang II stimulation of cultured rat aor-
tic vascular smooth muscle cells (VSMC); and, it has been previously re-
ported by others that the mechanism of this decrease in cultured kidney
cells is through cAM P dependent pathways. In this study we examined the
signal transduction pathway of this regUlation in quiescent VSMC. Total cel-
lular RNA was harvested after time course exposure to reagents, Northern
blotted and probed. AT1aR message abundance decreased beginning two
hours after exposure to ang II (10 nM) and reached a minimum at 4 hours
after stimulation of 25% of baseline level. The protein kinase C (PKC) stimula-
tor, PMA (50 nM), caused a decrease in ATlaR message level with the same
time course and to the same extent as ang II. Downregulation of PKC with 24
hour prior exposure to PDBU (500 nM) blocked the decrease in AT1aR mes-
sage caused by PMA. However, pretreatment with either PDBU orthe potent
PKC inhibitor calphostin C (50 nM) did not block the decrease of AT1aR mes-
sage level caused by ang II. In contrast. stimulation of cAMP with forskolin
(50 mM). cholera toxin (1 ang/ml) or the soluble analog 8-bromocyclic AM P(1
CMEC and in ARVM in a dose dependent manner that was maximal 4-8
hours after treatment. This effect of All was abolished after coincubation
with the angiotensin II receptor antagonist (AT-1) losartan (10-6 M), and the
ET-1 response was inhibited by the peptide endothelin type A (ETA) antago-
nist BO-123 (10-6 M). To determine whether bFGF itself autoregulates bFGF
mRNA abundance, ARVM and CMEC were treated with rh bFGF (20ng/mll. A
ninefold increase in bFGF mRNA was detected, thus indicating positive au-
toregulation. A marked induction of atrial natriuretic peptide mRNA, known
as a molecular marker of phenotype dedifferentiation in hypertrophy, was
observed after 24 and 48 hrs incubation with rh bFGF in ARVM. Finally, the
inflammatory cytokine interleukin 113 (rh IL-1f3) upregulates bFGF gene ex-
pression in ARVM, a response that could be amplified by interferon y (rm
IFN-y).
Thus, bFGF gene expression in ARVM and CMEC from rat heart is regu-
lated by All and ET-1 through the AT-1 receptor and (ETA) receptor subtypes.
The upregulation of bFGF gene transcription in response to various stimuli
known to affect myocyte and endothelial growth suggest a role for bFGF as a
signalling peptide in the hypertrophic response of adult ventricular myocytes
and cardiac microvascular endothelial cells.
Chi-Ming Wei. John Lust. Zvonimir Katusic. Michihisa Jougasaki, Denise Heublein,
Sharon Sandberg. Debra Lewis, Virginia Miller, Christopher McGregor,
John Burnett. Jr. Mayo Clinic, Rochester, MN
Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also
may modulate cardiac myocyte inotropism and growth via increases in
cGMP. While both the constitutive (cNOS) and inducible (iNOS)forms of nitric
oxide synthase have been detected in mammalian hearts, the overall pres-
ence and activity of the cNOS-NO-cGMP pathway in the normal and failing
human heart remains poorly defined. The present studies were designed to
investigate the cNOS-NO-cGMP pathway in normal and failing human atrial
and ventricular myocardium and to determine plasma NO and cGMP in the
presence and absence of CHE Myocardial tissue and plasma were obtained
from five end-stage heart failure patients undergoing cardiac transplantation
and five cardiac donors. Normal plasma NO and cGMP were also determined
in normal humans without disease. cNOS production and localization were
determined utilizing Northern blot analysis, in situ hybridization and immuno-
histochemistry with probes for endothelial-NOS and brain-NOS. Plasma and
tissue NO were measured by nitrate determination utilizing chemilumines-
cence. Northern blot analysis and in situ demonstrated cNOS to be present
and localized to atrial and ventricular myocytes in equal concentrations and
distributions in normal and failing hearts. Tissue NO as determined by nitrate
concentration was detectable and equal in normal and failing hearts while
plasma NO concentration tended to be increased in CHF patients. Cardiac
tissue cGMP paralleled tissue NO, although, plasma cGMP concentration
was significantly increased in CHF patients compared with normal subjects.
The present studies demonstrate that cNOS mRNA and cNOS protein are
present in the normal human heart and this cNOS-NO-cGMP pathway is pre-
served in the failing human heart. These studies suggest that this paracrine
and autocrine pathway may continue to function in the control of myocardial
function in the failing human myocardium.
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Mechanism of Decrease of Angiotensin II Receptor
Message Through Dual Signal Transduction
Pathways in Vascular Smooth Muscle
Stanley A. Rubin, Tim Bui, Lee Carter VA Medical Center, Long Beach and University
of California, Irvine, CA
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Anna Y. Hsu, Judith L. Swain University ofPennsylvania. Philadelphia. PA
Fibroblast growth factors (FGFs) have been demonstrated to regulate myo-
genic differentiation. Recently, forms of FGF have been generated that reside
in the cytoplasm and appear to be biologically active. suggesting that an in-
tracellular form of FGF may be able to transduce its signal through signaling
pathways independent of its interaction with cell surface (transmembrane)
FGF receptors (FGFR). We report in this study a potential mechanism by
which such signaling can be modulated by an intracellular form of the recep-
tor (I-FGFR). To generate this form of the receptor, the cDNA encoding the 2
IgG-like domain form of the murine transmembrane FGFR was mutated to re-
move its signal sequence and acidic box by PCR mutagenesis. This construct
was then epitope-tagged to allow it to be distinguished from the endogenous
surface FGF receptor. When the I-FGFR was transientlytransfected into COS
cells, a diffuse and reticular pattern was observed by indirect immunofluo-
rescence microscopy, indicating cytoplasmic localization with association to
organized intracellular structures, such as cytoskeleton or organellar mem-
brane. To test for the biologic effect of the I-FGFR, stable cell lines containing
the I-FGFR were generated in Sol 8 cells. Quadruplicate samples of four cell
lines expressing high levels of the I-FGFR, and four control cell lines trans-
fected with vector alone, were grown in mitogen poor medium (5% horse
serum). Their ability to differentiate was assessed by their levels of creatine
kinase activity normalized to total soluble protein (nmol NADPH/min/mg pro-
tein):
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Constitutive Expression of an Intracellular Form of
Fibroblast Growth Factor Receptor Triggers
Myogenic Differentiation
The results demonstrate that the intracellular form of the FGF receptor lo-
calizes to the cytoplasm of myocytes, and the increased expression of this
receptor isoform triggers myogenic differentiation. We propose that this re-
ceptor promotes differentiation by binding endogenous FGF, and thus inhibit-
ing the activity of FGF that normally preserves the undifferentiated state. The
ability to generate and express the intracellular FGF receptor, therefore, may
be a generally useful method of modulating FGF dependent regulation of
proliferation and differentiation of other cell types such as smooth muscle
and transformed cells.
The down-regulation of 131 AR and AT1 receptors was significantly related
(r = 0.62, n = 12, P < 0.05)
Conclusions: (1) Compared to 13 adrenergic receptors ang II receptors are
very low density in the human heart. (2) The AT1 receptor sUbtype predomi-
nates in the nonfailing human heart. (3) ATl but not AT2 receptors are down-
regulated in failing heart. (4) Down-regulation of Ang-II AT1 receptor is similar
in degree to down-regulation of 131-adrenergic receptors. These data suggest
that the AT1 and 131 receptors are respectively exposed to increased concen-
trations of mutually activatedlinduced norepinephrine and Ang-II in the failing
human heart.
Basic fibroblast growth factor (bFGF) has been shown to stimulate protein
synthesis in adult rat ventricular myocytes (ARVM) and DNA synthesis in mi-
crovascular endothelial cells (CM EC). To determine whether Angiotensin 11
(All) and Endothelin I (ET-1), known as peptides affecting myocyte growth,
regulate bFGF gene expression in the myocardium we examined the effects
of these two peptide autacoids on bFGF mRNA abundance in both cardiac
cell types. Baseline levels for bFGF mRNA in freshly isolated ARVM were
4 to 5 fold lower than in CMEC in RNase protection assays. All (10-6 -
10-8 M) and ET-1 (10-8 - 10-10 M) increased bFGF mRNA abundance in
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Regulation of Basic Fibroblast Growth Factor Gene
Expression in Rat Cardiac Microvascular Endothelial
Cells and Adult Ventricular Myocytes
Thomas A. Fischer. Krishna Singh, Alborz Alali, Min-Ae Lee, David Kaye. Albert
p. Gatbut. Jean Luc Balligand, Ralph A. Kelly, Thomas W. Smith Cardiovascular
Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical
School, Boston, MA
